{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-01-13&houseId=2&answer.answeringMemberPrinted=Earl+Howe", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2015-01-13&houseId=2&answer.answeringMemberPrinted=Earl+Howe", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-01-13&houseId=2&_metadata=all&answer.answeringMemberPrinted=Earl+Howe", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-01-13&_page=0&houseId=2&answer.answeringMemberPrinted=Earl+Howe", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-01-13&houseId=2&answer.answeringMemberPrinted=Earl+Howe", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-01-13&houseId=2&answer.answeringMemberPrinted=Earl+Howe", "items" : [{"_about" : "http://data.parliament.uk/resources/173519", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/173519/answer", "answerText" : {"_value" : "<p>Sodium valproate has been authorised since the early 1970\u2019s for the treatment of epilepsy. It was known at the time of licensing that valproate was associated with an increased risk of birth defects and it was authorised for the treatment of women of childbearing potential only where other treatments were ineffective. The authorised product information (Summary of Product Characteristics or SPC and Patient Information Leaflet or PIL) contain warnings about the risks associated with use in pregnancy.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) initiated a Europe-wide review of the risk of developmental disorders in October 2013 following publication of studies which provided further information on the magnitude and nature of the risk of developmental disorders in children born to mothers who took valproate in pregnancy. The Europe-wide review, led by the United Kingdom and the Netherlands, was completed in November 2014 and MHRA is working to fully implement the conclusions of that review which are binding in all Member States. There will be a mandatory requirement for all manufacturers to update the valproate SPC and PIL with strengthened warnings and in addition new educational materials will be provided to healthcare professionals and patients.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2015-01-26", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL4102"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-01-26T12:28:03.583Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pregnancy: Sodium Valproate"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government, following the findings of the European Medicines Agency review of Valproate in pregnancy, and the past issue of the availability of information to patients, why the new instructions from the European Medicines Agency have not become mandatory.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
      ], "uin" : "HL4101"}
    , {"_about" : "http://data.parliament.uk/resources/173520", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/173520/answer", "answerText" : {"_value" : "<p>Sodium valproate has been authorised since the early 1970\u2019s for the treatment of epilepsy. It was known at the time of licensing that valproate was associated with an increased risk of birth defects and it was authorised for the treatment of women of childbearing potential only where other treatments were ineffective. The authorised product information (Summary of Product Characteristics or SPC and Patient Information Leaflet or PIL) contain warnings about the risks associated with use in pregnancy.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) initiated a Europe-wide review of the risk of developmental disorders in October 2013 following publication of studies which provided further information on the magnitude and nature of the risk of developmental disorders in children born to mothers who took valproate in pregnancy. The Europe-wide review, led by the United Kingdom and the Netherlands, was completed in November 2014 and MHRA is working to fully implement the conclusions of that review which are binding in all Member States. There will be a mandatory requirement for all manufacturers to update the valproate SPC and PIL with strengthened warnings and in addition new educational materials will be provided to healthcare professionals and patients.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2015-01-26", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL4101"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-01-26T12:28:03.67Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pregnancy: Sodium Valproate"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government whether they intend to issue an apology for the failure to inform female patients of the dangers of Valproate in pregnancy and the harm caused to children as a result.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
      ], "uin" : "HL4102"}
    , {"_about" : "http://data.parliament.uk/resources/173537", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/173537/answer", "answerText" : {"_value" : "<p>Health Education England (HEE) plans to undertake a review of the medical student intake in 2015 in the context of the HEE Strategic Framework 15, the HEE Workforce Plan for England 2015-16, and the recently published NHS England Five Year Forward View.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Working with the Chief Dental Officer for England, HEE took the decision to recommend a reduction in the 2014 student dental intake by 10%. This was in response to a number of issues including detailed analysis supplied by the Centre for Workforce Intelligence that highlighted key changes in the improvement in dental health within England and the need for NHS England to ensure it had available the appropriate workforce to meet the needs of the service going forward.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2015-01-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-01-26T12:46:52.017Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medicine: Education"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answers by Earl Howe on 24 October 2014 (HL2125 and HL2126) and 1 July 2013 (WA 191\u20132), why the review of medical and dental student intakes recommended by the Health and Education National Strategic Exchange for 2014, which was to be led by Health Education England, did not take place; and why, in its absence, they reconsidered the policy of reducing student intake.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2479", "label" : {"_value" : "Biography information for Lord Laird"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Laird"}
      ], "uin" : "HL4119"}
    , {"_about" : "http://data.parliament.uk/resources/173538", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/173538/answer", "answerText" : {"_value" : "<p><em>There are more than 1,000 more general practitioners (GPs) now working and training in the National Health Service than from the position in September 2010, the most recent figures after the General Election \u2013 these data are published once a year in September. The next census as at 30 September 2014 will be published in March 2015.<\/em><\/p><p> <\/p><p><em> <\/em><\/p><p> <\/p><p><em>Transforming Primary Care <\/em>set out the intention to make available around 10,000 primary and community health and care professionals by 2020, in support of the shift in how care will be provided. Bringing forward substantial numbers of new GPs through training is a key part of this, and Health Education England\u2019s (HEE) mandate commitment will increase the total number of GPs available by 5,000.<\/p><p> <\/p><p><em> <\/em><\/p><p> <\/p><p><em>In order to understand the needs of the primary care workforce of the future, HEE has commissioned an independent review. On 10 December 2014, HEE announced that Professor Martin Roland, Professor of Health Services Research, University of Cambridge, will Chair the Primary Care Workforce Commission. <\/em><\/p><p> <\/p><p><em> <\/em><\/p><p> <\/p><p><em>The work was commissioned by HEE at the request of the Secretary of State for Health, due to the future health and care system requiring greater emphasis on community, primary and integrated services, and to ensure that we have the primary care workforce to meet the changing needs for healthcare, therefore it will focus on: <\/em><\/p><p> <\/p><p><em> <\/em><\/p><p> <\/p><p><em>- <\/em><em>patient and population need; <\/em><\/p><p> <\/p><p><em>- <\/em><em>emerging models of care to respond to the population need; <\/em><\/p><p> <\/p><p><em>- <\/em><em>maximising new skill sets; and<\/em><\/p><p> <\/p><p><em>- <\/em><em>education and training. <\/em><\/p><p> <\/p><p><em> <\/em><\/p><p> <\/p><p><em>HEE are currently implementing a number of projects to support recruitment into practice. This includes a pre-GP year pilot in five Local Education and Training Boards that provides targeted educational development for those expressing interest in general practice, and the launch of a primary and community care programme.<\/em><\/p><p> <\/p><p> <\/p><p> <\/p><p>HEE plan to undertake a review of the medical student intake in 2015 in the context of the HEE Strategic Framework 15, the HEE Workforce Plan for England 2015-16, and the recently published NHS England Five Year Forward View.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2015-01-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-01-26T13:00:07.307Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "General Practitioners"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answer by Earl Howe on 24 October 2014 (HL2125 and HL2126), what plans they have to address the current shortage of general practitioners; whether they will review their decision to reduce the number of students entering medical school this year; and whether they intend to rely on foreign medical graduates coming to this country to fill vacancies for the foreseeable future.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2479", "label" : {"_value" : "Biography information for Lord Laird"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Laird"}
      ], "uin" : "HL4120"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}